207 related articles for article (PubMed ID: 34975892)
1. Treatment With CD52 Antibody Protects Neurons in Experimental Autoimmune Encephalomyelitis Mice During the Recovering Phase.
Hao W; Luo Q; Menger MD; Fassbender K; Liu Y
Front Immunol; 2021; 12():792465. PubMed ID: 34975892
[TBL] [Abstract][Full Text] [Related]
2. Anti-CD52 antibody treatment depletes B cell aggregates in the central nervous system in a mouse model of multiple sclerosis.
Simon M; Ipek R; Homola GA; Rovituso DM; Schampel A; Kleinschnitz C; Kuerten S
J Neuroinflammation; 2018 Aug; 15(1):225. PubMed ID: 30098594
[TBL] [Abstract][Full Text] [Related]
3. Immune cell derived BDNF does not mediate neuroprotection of the murine anti-CD52 antibody in a chronic autoimmune mouse model.
Demir S; Pitarokoili K; Linker R; Gold R
J Neuroimmunol; 2019 Mar; 328():78-85. PubMed ID: 30623801
[TBL] [Abstract][Full Text] [Related]
4. The therapeutic effect of anti-CD52 treatment in murine experimental autoimmune encephalomyelitis is associated with altered IL-33 and ST2 expression levels.
Barbour M; Wood R; Hridi SU; Wilson C; McKay G; Bushell TJ; Jiang HR
J Neuroimmunol; 2018 May; 318():87-96. PubMed ID: 29526407
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of SIRT1 protein in neurons protects against experimental autoimmune encephalomyelitis through activation of multiple SIRT1 targets.
Nimmagadda VK; Bever CT; Vattikunta NR; Talat S; Ahmad V; Nagalla NK; Trisler D; Judge SI; Royal W; Chandrasekaran K; Russell JW; Makar TK
J Immunol; 2013 May; 190(9):4595-607. PubMed ID: 23547115
[TBL] [Abstract][Full Text] [Related]
6. Alteration of CD39+Foxp3+ CD4 T cell and cytokine levels in EAE/MS following anti-CD52 treatment.
Pant AB; Wang Y; Mielcarz DW; Kasper EJ; Telesford KM; Mishra M; Haque A; Channon JY; Kasper LH; Begum-Haque S
J Neuroimmunol; 2017 Feb; 303():22-30. PubMed ID: 28087077
[TBL] [Abstract][Full Text] [Related]
7. Treatment with a recombinant human IgM that recognizes PSA-NCAM preserves brain pathology in MOG-induced experimental autoimmune encephalomyelitis.
Lemus HN; Warrington AE; Denic A; Wootla B; Rodriguez M
Hum Antibodies; 2017; 25(3-4):121-129. PubMed ID: 28269761
[TBL] [Abstract][Full Text] [Related]
8. Targeting CD52 does not affect murine neuron and microglia function.
Ellwardt E; Vogelaar CF; Maldet C; Schmaul S; Bittner S; Luchtman D
Eur J Pharmacol; 2020 Mar; 871():172923. PubMed ID: 31962100
[TBL] [Abstract][Full Text] [Related]
9. Bu Shen Yi Sui capsule promotes remyelination correlating with Sema3A/NRP-1, LIF/LIFR and Nkx6.2 in mice with experimental autoimmune encephalomyelitis.
Zhao PY; Wang YQ; Liu XH; Zhu YJ; Zhao H; Zhang QX; Qi F; Li JL; Zhang N; Fan YP; Li KN; Zhao YY; Lei JF; Wang L
J Ethnopharmacol; 2018 May; 217():36-48. PubMed ID: 29428242
[TBL] [Abstract][Full Text] [Related]
10. Nicotinamide adenine dinucleotide treatment alleviates the symptoms of experimental autoimmune encephalomyelitis by activating autophagy and inhibiting the NLRP3 inflammasome.
Wang X; Li B; Liu L; Zhang L; Ma T; Guo L
Int Immunopharmacol; 2021 Jan; 90():107092. PubMed ID: 33290962
[TBL] [Abstract][Full Text] [Related]
11. Surfen, a proteoglycan binding agent, reduces inflammation but inhibits remyelination in murine models of Multiple Sclerosis.
Warford JR; Lamport AC; Clements DR; Malone A; Kennedy BE; Kim Y; Gujar SA; Hoskin DW; Easton AS
Acta Neuropathol Commun; 2018 Jan; 6(1):4. PubMed ID: 29301568
[TBL] [Abstract][Full Text] [Related]
12. Intranasal delivery of FSD-C10, a novel Rho kinase inhibitor, exhibits therapeutic potential in experimental autoimmune encephalomyelitis.
Li YH; Yu JZ; Liu CY; Zhang H; Zhang HF; Yang WF; Li JL; Feng QJ; Feng L; Zhang GX; Xiao BG; Ma CG
Immunology; 2014 Oct; 143(2):219-29. PubMed ID: 24749492
[TBL] [Abstract][Full Text] [Related]
13. Quetiapine, an atypical antipsychotic, is protective against autoimmune-mediated demyelination by inhibiting effector T cell proliferation.
Mei F; Guo S; He Y; Wang L; Wang H; Niu J; Kong J; Li X; Wu Y; Xiao L
PLoS One; 2012; 7(8):e42746. PubMed ID: 22912731
[TBL] [Abstract][Full Text] [Related]
14. Distinct pathological patterns in relapsing-remitting and chronic models of experimental autoimmune enchephalomyelitis and the neuroprotective effect of glatiramer acetate.
Aharoni R; Vainshtein A; Stock A; Eilam R; From R; Shinder V; Arnon R
J Autoimmun; 2011 Nov; 37(3):228-41. PubMed ID: 21752599
[TBL] [Abstract][Full Text] [Related]
15. Low dose dextromethorphan attenuates moderate experimental autoimmune encephalomyelitis by inhibiting NOX2 and reducing peripheral immune cells infiltration in the spinal cord.
Chechneva OV; Mayrhofer F; Daugherty DJ; Pleasure DE; Hong JS; Deng W
Neurobiol Dis; 2011 Oct; 44(1):63-72. PubMed ID: 21704706
[TBL] [Abstract][Full Text] [Related]
16. Anti-CD52 blocks EAE independent of PD-1 signals and promotes repopulation dominated by double-negative T cells and newly generated T and B cells.
Haile Y; Adegoke A; Laribi B; Lin J; Anderson CC
Eur J Immunol; 2020 Sep; 50(9):1362-1373. PubMed ID: 32388861
[TBL] [Abstract][Full Text] [Related]
17. Neuroprotective effects of α-lipoic acid on long-term experimental autoimmune encephalomyelitis.
Li B; Tan GJ; Lin HQ; Zhang JN; Guo L; Chen LP
Eur Rev Med Pharmacol Sci; 2018 Oct; 22(19):6517-6528. PubMed ID: 30338822
[TBL] [Abstract][Full Text] [Related]
18. The small molecule fibroblast growth factor receptor inhibitor infigratinib exerts anti-inflammatory effects and remyelination in a model of multiple sclerosis.
Rajendran R; Rajendran V; Böttiger G; Stadelmann C; Shirvanchi K; von Au L; Bhushan S; Wallendszus N; Schunin D; Westbrock V; Liebisch G; Ergün S; Karnati S; Berghoff M
Br J Pharmacol; 2023 Dec; 180(23):2989-3007. PubMed ID: 37400950
[TBL] [Abstract][Full Text] [Related]
19. Ellagic acid protects from myelin-associated sphingolipid loss in experimental autoimmune encephalomyelitis.
Busto R; Serna J; Perianes-Cachero A; Quintana-Portillo R; García-Seisdedos D; Canfrán-Duque A; Paino CL; Lerma M; Casado ME; Martín-Hidalgo A; Arilla-Ferreiro E; Lasunción MA; Pastor Ó
Biochim Biophys Acta Mol Cell Biol Lipids; 2018 Sep; 1863(9):958-967. PubMed ID: 29793057
[TBL] [Abstract][Full Text] [Related]
20. Regulatory B Cells Normalize CNS Myeloid Cell Content in a Mouse Model of Multiple Sclerosis and Promote Oligodendrogenesis and Remyelination.
Pennati A; Nylen EA; Duncan ID; Galipeau J
J Neurosci; 2020 Jun; 40(26):5105-5115. PubMed ID: 32430295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
